Kateland R. Antonazzo

Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV)

Julie A. Marusich, Kateland R. Antonazzo, Jenny L. Wiley et al. · Neuropharmacology · 2014 · 199 citations · Full text

Molecular Pharmacology, Novel Synthetic Stimulants, Pharmaceutical Science +8

AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol–Like Effects in Mice

Jenny L. Wiley, Julie A. Marusich, Timothy W. Lefever et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 116 citations · Full text

Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model

Timothy W. Lefever, Julie A. Marusich, Kateland R. Antonazzo et al. · Pharmacology Biochemistry and Behavior · 2014 · 63 citations · Full text

Cannabis Use, Substance Abuse, Psychoactive Drug +11

Evaluation of sex differences in cannabinoid dependence

Julie A. Marusich, Timothy W. Lefever, Kateland R. Antonazzo et al. · Drug and Alcohol Dependence · 2014 · 47 citations

Cannabis Use, Substance Abuse, Substance Use +8

The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue

Julie A. Marusich, Kateland R. Antonazzo, Bruce E. Blough et al. · Neuropharmacology · 2015 · 22 citations · Full text

Psychoactive Drug, Monoamine Transporters, Neurophysiology +13